Navigation Links
Repligen Reports Third Quarter Fiscal Year 2009 Financial Results
Date:2/5/2009

clinical trial in which approximately 150 patients with bipolar depression will receive either RG2417 or a placebo twice a day for eight weeks. This study is designed to assess the safety and efficacy of RG2417 on the symptoms of depression as measured by the Montgomery-Asberg Depression Rating Scale (MADRS) and the Clinical Global Impression of Change in Bipolar Disorder scale (CGI-BP-C). This study is based on the positive results of a Phase 2a study in which 83 patients received either RG2417 or a placebo twice a day for six weeks. Over the six-week treatment period, the study demonstrated a statistically significant improvement in the symptoms of depression in the patients receiving RG2417 when compared to placebo on the MADRS (p=0.01) and the CGI-BP-C (p=0.04).

RG2833 for Friedreich's Ataxia and Huntington's Disease

We are currently developing inhibitors of histone deacetylases (HDACs) which may have utility in treating progressive, inherited neurodegenerative diseases such as Friedreich's ataxia and Huntington's disease. We have identified several potential clinical candidates and are further characterizing these leads in animal models for their pharmacologic, toxicologic and pharmacodynamic profiles.

Stock Repurchase Program

In June 2008, Repligen announced that its Board of Directors authorized the repurchase of up to 1.25 million shares of its common stock. As of December 31, 2008, the Company has repurchased approximately 493,000 shares for an aggregate cost of approximately $2.0 million.

Quarterly Conference Call

Repligen will host a conference call and webcast on Thursday, February 5th at 10:00 a.m. EST, to review financial results. This call can be accessed via Repligen's website at www.repligen.com or by calling (866) 383-8008 for domestic calls and (617) 597-5341 for internation
'/>"/>

SOURCE Repligen Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Repligen to Present at the BIO CEO & Investor Conference Monday, February 9th, 11:30 a.m. EST
2. Repligen Announces Conference Call of Third Quarter Fiscal Year 2009 Results
3. Repligen to Present at the Rodman & Renshaw 10th Annual Healthcare Conference Monday, November 10th, 4:55 p.m. EST
4. Repligen to Present at the 2008 UBS Global Life Sciences Conference Wednesday, September 24th, 1:00 p.m. EDT
5. Repligen Announces Publication of Positive Results with Proprietary HDAC Inhibitor in Huntingtons Disease Model
6. Repligen Receives Research Grants to Support Friedreichs Ataxia Development Program
7. Repligen Announces Conference Call of First Quarter Fiscal Year 2009 Results
8. Repligen Reports Fourth Quarter and Fiscal Year 2008 Financial Results
9. Repligen Announces Settlement with Bristol-Myers Squibb in Orencia(R) Lawsuit
10. Repligen Announces Conference Call of Third Quarter Fiscal Year 2008 Results
11. Sangamo BioSciences Reports Fourth Quarter and Full Year 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... (PRWEB) July 10, 2014 Understanding the ... channel-expressing cell lines, and the gap that currently exists ... that expand its industry-leading portfolio of validated ion channel ... ion channel-expressing cell lines, as ion channels control many ... control this activity creates the potential to treat a ...
(Date:7/10/2014)... EvoDerma ’s NOOME Anti-Aging Motion has been ... comes with a second treatment cup to help prevent and ... cup is thinner on the edges for a softer contact ... and uneven surfaces on the face, neck and décolleté. Choose ... on areas such as the cheeks and neck, or opt ...
(Date:7/10/2014)... 2014 /PRNewswire-iReach/ -- Tute Genomics, the leader ... an agreement with Lineagen, Inc., to provide ... Dx PLUS.  Lineagen, focused on the ... currently offers FirstStep Dx PLUS, a ... by healthcare providers as a first-line genetic ...
(Date:7/10/2014)... D.C., June 17, 2014 Using microscopic polymer ... specific gases, researchers at MIT,s Quantum Photonics Laboratory ... levels in the parts-per-billion range. Optical sensors are ... their high signal-to-noise ratio, compact, lightweight nature, and ... gas sensors had been developed before, the MIT ...
Breaking Biology Technology:Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells 2Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells 3Introducing a New Bonus Treatment Cup for EvoDerma’s NOOME Anti-Aging Motion 2Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 2Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 3Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 4Swell new sensors 2
... Palatin Technologies, Inc. (NYSE Amex: PTN ... clinical trial of AZD2820, a subcutaneously-administered peptide melanocortin receptor ... the treatment of obesity. AZD2820 is a clinical candidate ... Palatin Technologies. Obesity is a global problem, ...
... 4, 2011   ReportsnReports announces ... Hospital-Acquired Infections (HAI) Diagnostics Market in its store ... for Alternatives to Needle-Based Systems for Vaccine and Biologics ... a focal point of competition within the pharmaceutical industry. The ...
... coatings devised by researchers from the National Institute of ... conventional flame retardants used in the polyurethane foam of ... and perhaps by as much as 1,130 percent. ... Polymer ,* suggest that significant fire-safety advantages can be ...
Cached Biology Technology:Palatin Announces Commencement of a Phase 1 Trial for Obesity Compound in Collaboration with AstraZeneca 2Palatin Announces Commencement of a Phase 1 Trial for Obesity Compound in Collaboration with AstraZeneca 3ReportsnReports - Needle-Free Drug Delivery Market & Hospital-Acquired Infections (HAI) Diagnostics Market Reports 2ReportsnReports - Needle-Free Drug Delivery Market & Hospital-Acquired Infections (HAI) Diagnostics Market Reports 3ReportsnReports - Needle-Free Drug Delivery Market & Hospital-Acquired Infections (HAI) Diagnostics Market Reports 4Novel coatings show great promise as flame retardants in polyurethane foam 2
(Date:7/10/2014)... 2, 2014  Unisys Corporation,s (NYSE: UIS ) ... N.V., today announced that it has been selected by the ... a new Basic Provision Biometrics solution for penitentiaries across ... the contract with a solution based on its open standards-based ... of the contract is up to seven years, with the ...
(Date:7/10/2014)... SHELTON, Conn. , July 2, 2014 NXT-ID, Inc., ... market, reports that CEO Mr. Gino Pereira was ... radio show in Tampa Florida . Mr. ... radio host Cedric Harris and how the Wocket™ ... secure alternative.  Cedric Harris tells ...
(Date:7/10/2014)... -- Research and Markets ( http://www.researchandmarkets.com/research/h7h8lq/gesture ) has ... Recognition & Touch-Less Sensing (2D, 3D, Ultrasonic, IR, ... to their offering http://photos.prnewswire.com/prnh/20130307/600769 ... Sensing Market to Grow Exponentially. Touch-less sensing applications ... companies were unable to leverage this technology due ...
Breaking Biology News(10 mins):Unisys Delivers New Basic Provision Biometrics Solution to Dutch Custodial Institutions Service 2Unisys Delivers New Basic Provision Biometrics Solution to Dutch Custodial Institutions Service 3Security and Your Money: Tampa Bay Radio Host Cedric Harris Talks to NXT-ID CEO Mr. Gino Pereira about the Wocket Smart Wallet 2Security and Your Money: Tampa Bay Radio Host Cedric Harris Talks to NXT-ID CEO Mr. Gino Pereira about the Wocket Smart Wallet 3Security and Your Money: Tampa Bay Radio Host Cedric Harris Talks to NXT-ID CEO Mr. Gino Pereira about the Wocket Smart Wallet 4Global Gesture Recognition & Touch-Less Sensing (2D, 3D, Ultrasonic, IR, Capacitive) Market - Forecasts to 2020 2
... The ability to shrink laboratory-scale processes to automated ... example, inexpensive and highly portable devices that process ... anthrax are needed by the U.S. military and ... of "lab-on-a-chip" technology is the need for miniaturized ...
... from reproductive biologists at the University of Massachusetts Amherst, with ... sperm capacitation that may one day improve success rates of ... problems, and may eventually lead to a male contraceptive. ... down the road, says Pablo Visconti, lead UMass Amherst author, ...
... review suggests that omega-3 fatty acids taken in excess could ... standards based on the best available evidence need to be ... years ago may not be as clear cut as we ... Public Health and Human Sciences and a coauthor on the ...
Cached Biology News:Super-thin membranes clear the way for chip-sized pumps 2Reproductive biologists move in vitro fertilization knowledge forward 2Reproductive biologists move in vitro fertilization knowledge forward 3Excess omega-3 fatty acids could lead to negative health effects 2Excess omega-3 fatty acids could lead to negative health effects 3
... sensitive laser confocal systems designed for rapid ... that meet your expectations, differentiating between a ... the signal on the bottom as well ... for increased sensitivity. Results with VersArray ChipReader ...
... perform 96 assays on four slides. The ... slides with 96 (6mm x 7mm) individual ... expression, or screening analysis studies. Unlike other ... gasket, eliminating the presence of contaminating adhesives. ...
... with sequence siTrio siRNA --- a ... target gene of interestis our most popular product. ... 75% knockdown of your target gene when used ... and confirmation of optimal transfection with one of ...
... Macro-Prep ion exchange media are rigid ... allows high flow rates at moderate pressures, ... ionic sites, and the hydrophilic matrix reduces ... a high-capacity strong anion exchanger with very ...
Biology Products: